Dabigatran-induced nephropathy and its successful treatment with Idarucizumab - case report and literature review

Jenan Awesat, Iftach Sagy, Yosef S. Haviv, Anat Rabinovich, Alan Jotkowitz, Elena Shleyfer, Leonid Barski

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations

Abstract

Background: Anticoagulant induced renal injury has been previously described with Warfarin treatment. In the last decade direct oral anticoagulants (DOAC) were introduced. They include direct inhibitors of factor Xa (Rivaroxaban, Apixaban, Edoxaban) and a thrombin inhibitor (Dabigatran). There are isolated reports describing acute kidney injury (AKI) due to the use of DOACs. Case report: We report a clinical case of an 80-year-old patient recently started on Dabigatran for new onset atrial fibrillation. She presented with AKI and hematuria, urine specimen showed RBC casts, and a working diagnosis of anticoagulant nephropathy due to Dabigatran was made. During hospitalization she was treated with Idarucizumab with a full recovery of renal function. To the best of our knowledge, there are 4 published case reports describing kidney injury produced by Dabigatran. Conclusion: The use of DOACs is increasing rapidly, with increasing concern about its safety profile and, in particular, its potential harmful effect on renal function. As described in our case, treatment with Praxbind for Dabigatran induced kidney injury may be an acceptable management strategy that may obviate the need for urgent dialysis in selected cases by complete reversal of the AKI.

Original languageEnglish
Pages (from-to)120-122
Number of pages3
JournalThrombosis Research
Volume169
DOIs
StatePublished - 1 Sep 2018
Externally publishedYes

Keywords

  • Acute kidney injury
  • Direct oral anticoagulants (DOAC'S)
  • Idarucizumab

Fingerprint

Dive into the research topics of 'Dabigatran-induced nephropathy and its successful treatment with Idarucizumab - case report and literature review'. Together they form a unique fingerprint.

Cite this